Abstract
Melanoma patients with additional positive lymph nodes in the completion lymph node dissection (CLND) following a positive sentinel lymph node (SLN) biopsy would have a poorer prognosis than patients with no additional positive lymph nodes. We hypothesize that the progression of disease from the SLN to the non-SLN compartment is orderly and is associated with the worsening of the disease status. Thus, the SLN and non-SLN compartments are biologically different in that cancer cells, in general, arrive in the SLN compartment before spreading to the non-SLN compartment. To validate this concept, we used a large cohort of melanoma patients from our prospective SLN database in an academic tertiary medical center. Adult cutaneous melanoma patients (n = 291) undergoing CLND after a positive SLN biopsy from 1994 to 2009 were analyzed. Comparison of 5-year disease-free survival and 5-year overall survival between positive (n = 66) and negative (n = 225) CLND groups was made. The 5-year disease-free survival rates were 55% (95% CI 49–62%) for patients with no additional LN on CLND versus 14% (95% CI 8–26%) in patients with positive LN on CLND (p < 0.0001, log-rank test). The median disease-free survival time was 7.4 years with negative CLND (95% CI 4.4–15+ years) and 1.2 years with positive CLND (95% CI 1.0–1.8 years). The 5-year overall survival rates were 67% (95% CI 61–74%) for negative CLND versus 38% (95% CI 28–52%) for positive CLND (p < 0.0001, log-rank test). The median overall survival time was 12.1 years for negative CLND (95% CI 9.3–15+ years) and 2.5 years for positive CLND (95% CI 2.2–5.7 years). This study shows that CLND status is a significant prognostic factor for patients with positive SLNs undergoing CLND. Also, it suggests an orderly progression of metastasis from the SLN to the non-SLN compartment. Thus, the SLN in the regional nodal basin draining the primary melanoma may serve as an important gateway for metastasis to the non-SLN compartment and beyond to the systemic sites.
Similar content being viewed by others
References
Morton DL, Wen DR, Wong JH et al (1992) Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127:392–399
Coit DG, Thompson JA, Andtbacka R et al (2014) Melanoma, version 4.2014. J Natl Compr Canc Netw 12:621–629
Han D, Zager JS, Shyr Y et al (2013) Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol 31:4387–4393
Lee JH, Essner R, Torisu-Itakura H et al (2004) Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol 22:3677–3684
Murali R, Desilva C, Thompson JF et al (2010) Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. J Clin Oncol 28:4441–4449
van der Ploeg AP, van Akkooi AC, Rutkowski P et al (2011) Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol 29:2206–2214
van Akkooi AC, Nowecki ZI, Voit C et al (2008) Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes. Ann Surg 248:949–955
Nagaraja V, Eslick GD (2013) Is complete lymph node dissection after a positive sentinel lymph node biopsy for cutaneous melanoma always necessary? A meta-analysis. Eur J Surg Oncol 39:669–680
Baehner FL, Li R, Jenkins T et al (2012) The impact of primary melanoma thickness and microscopic tumor burden in sentinel lymph nodes on melanoma patient survival. Ann Surg Oncol 19:1034–1042
Han D, Thomas DC, Zager JS et al (2016) Clinical utilities and biological characteristics of melanoma sentinel lymph nodes. World J Clin Oncol 7:174–188
Morton DL (2012) Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma. Clin Exp Metastasis 29:699–706
Kunte C, Geimer T, Baumert J et al (2010) Prognostic factors associated with sentinel lymph node positivity and effect of sentinel status on survival: an analysis of 1049 patients with cutaneous melanoma. Melanoma Res 20:330–337
Brown RE, Ross MI, Edwards MJ et al (2010) The prognostic significance of nonsentinel lymph node metastasis in melanoma. Ann Surg Oncol 17:3330–3335
Glumac N, Hocevar M, Zadnik V et al (2008) Sentinel lymph node micrometastasis may predict non-sentinel involvement in cutaneous melanoma patients. J Surg Oncol 98:46–48
Rutkowski P, Szydlowski K, Nowecki ZI et al (2015) The long-term results and prognostic significance of cutaneous melanoma surgery using sentinel node biopsy with triple technique. World J Surg Oncol 13:299
Ul-Mulk J, Holmich LR (2012) Lymph node dissection in patients with malignant melanoma is associated with high risk of morbidity. Dan Med J 59:A4441
Satzger I, Meier A, Zapf A et al (2014) Is there a therapeutic benefit of complete lymph node dissection in melanoma patients with low tumor burden in the sentinel node? Melanoma Res 24:454–461
Morton DL, Cochran AJ, Thompson JF, et al (2005) Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 242:302–311 (discussion 311-3)
Guggenheim MM, Hug U, Jung FJ et al (2008) Morbidity and recurrence after completion lymph node dissection following sentinel lymph node biopsy in cutaneous malignant melanoma. Ann Surg 247:687–693
Kretschmer L, Thoms KM, Peeters S et al (2008) Postoperative morbidity of lymph node excision for cutaneous melanoma-sentinel lymphonodectomy versus complete regional lymph node dissection. Melanoma Res 18:16–21
van Akkooi AC, Bouwhuis MG, van Geel AN et al (2007) Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma. Eur J Surg Oncol 33:102–108
Wrightson WR, Wong SL, Edwards MJ et al (2003) Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol 10:676–680
Holmes EC, Moseley HS, Morton DL et al (1977) A rational approach to the surgical management of melanoma. Ann Surg 186:481–490
Wong SL, Morton DL, Thompson JF et al (2006) Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol 13:809–816
van der Ploeg AP, van Akkooi AC, Rutkowski P et al (2012) Prognosis in patients with sentinel node-positive melanoma without immediate completion lymph node dissection. Br J Surg 99:1396–1405
van Akkooi AC, de Wilt JH, Verhoef C et al (2006) Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann Oncol 17:1578–1585
van der Ploeg AP, van Akkooi AC, Haydu LE et al (2014) The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients. Eur J Cancer 50:111–120
Averbook BJ (2011) Mitotic rate and sentinel lymph node tumor burden topography: integration into melanoma staging and stratification use in clinical trials. J Clin Oncol 29:2137–2141
Mosquera C, Vora HS, Vohra N et al (2017) Population-based analysis of completion lymphadenectomy in intermediate-thickness melanoma. Ann Surg Oncol 24(1):127–134. doi:10.1245/s10434-016-5460-4
Kroon HM, Lowe L, Wong S et al (2007) What is a sentinel node? Re-evaluating the 10% rule for sentinel lymph node biopsy in melanoma. J Surg Oncol 95:623–628
Murphy AD, Britten A, Powell B (2014) Hot or not? The 10% rule in sentinel lymph node biopsy for malignant melanoma revisited. J Plast Reconstr Aesthet Surg 67:316–319
Giuliano AE, Dale PS, Turner RR et al (1995) Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 222:394–399 (discussion 399–401)
Cady B (1984) Lymph node metastases. Indicators, but not governors of survival. Arch Surg 119:1067–1072
Hellman S (1997) Darwin’s clinical relevance. Cancer 79:2275–2281
Leung AM, Morton DL, Ozao-Choy J et al (2013) Staging of regional lymph nodes in melanoma: a case for including nonsentinel lymph node positivity in the American Joint Committee on Cancer staging system. JAMA Surg 148:879–884
Roka F, Mastan P, Binder M et al (2008) Prediction of non-sentinel node status and outcome in sentinel node-positive melanoma patients. Eur J Surg Oncol 34:82–88
Hellman S (1994) Karnofsky Memorial Lecture. Natural history of small breast cancers. J Clin Oncol 12:2229–2234
Leong SP, Tseng WW (2014) Micrometastatic cancer cells in lymph nodes, bone marrow, and blood: Clinical significance and biologic implications. CA Cancer J Clin 64:195–206
Giuliano AE, Hunt KK, Ballman KV et al (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305:569–575
Leong SP, Witte M (2012) Biomarkers of cancer metastasis through the lymphovascular system: future perspectives. Clin Exp Metastasis 29(7):861–864
Holtkamp LH, Wang S, Wilmott JS et al (2015) Detailed pathological examination of completion node dissection specimens and outcome in melanoma patients with minimal (< 0.1 mm) sentinel lymph node metastases. Ann Surg Oncol 22:2972–2977
Leiter U, Stadler R, Mauch C et al (2016) Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol 17:757–767
Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, Wouters MWJM, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Rossi CR, Neves RI, Trocha SD, Wright F, Byrd DR, Matter M, Hsueh E, MacKenzie-Ross A, Johnson DB, Terheyden P, Berger AC, Huston TL, Wayne JD, Smithers BM, Neuman HB, Schneebaum S, Gershenwald JE, Ariyan CE, Desai DC, Jacobs L, McMasters KM, Gesierich A, Hersey P, Bines SD, Kane JM, Barth RJ, McKinnon G, Farma JM, Schultz E, Vidal-Sicart S, Hoefer RA, Lewis JM, Scheri R, Kelley MC, Nieweg OE, Noyes RD, Hoon DSB, Wang HJ, Elashoff DA, Elashoff RM (2017) Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 376(23):2211–2222
Leong SP (2013) Compartmentalizing sentinel lymph nodes and nonsentinel lymph nodes in regional lymph nodes draining the primary melanoma. JAMA Surg 148:884–885
Acknowledgements
Dr. Cleaver is supported by “E.A.Dickson Emeritus Professorship” and by a gift from the Tumori Foundation courtesy of Dr. Devron Char, CPMC.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rios-Cantu, A., Lu, Y., Melendez-Elizondo, V. et al. Is the non-sentinel lymph node compartment the next site for melanoma progression from the sentinel lymph node compartment in the regional nodal basin?. Clin Exp Metastasis 34, 345–350 (2017). https://doi.org/10.1007/s10585-017-9854-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10585-017-9854-x